IRSF announces the availability of Regular Research grants for international biomedical research to promote the understanding of MeCP2 in the pathogenesis of the neurobehavioral phenotype of Rett syndrome (RTT). We seek to gain a better understanding of the underlying pathology of the disorder leading to an amelioration of the symptoms and a cure for RTT.
IRSF announces the availability of HeART (Help Accelerate RTT Therapeutics) and ANGEL (Advanced Neurotherapeutic Grant of Excellence) grant awards to promote the development and testing of therapeutics to treat and reverse Rett syndrome (RTT) and its symptoms. These award mechanisms seek to facilitate the development and testing of novel therapeutics targeting the underlying pathology of the disorder, thereby leading to an amelioration of symptoms or ultimately a pharmacological reversal of RTT.
IRSF announces the availability of Mentored Training Fellowships to support scientists early in their career to in both basic and clinical research in the field of Rett syndrome so that they become successful, independent basic research scientists and clinical investigators. These talented researchers will be the future leaders in the Basic, Translational and Clinical research areas for Rett syndrome.
Considering the interdisciplinary nature of both Basic and Translational Research projects, collaborative studies among geneticists, molecular biologists, neuroscientists, child neurologists, medicinal chemists and pharmacologists engaged in drug discovery and other clinical or basic researchers are encouraged. Teams working together from different institutions as well as within pharmaceutical and biotechnology industries are strongly encouraged.
Be sure to read our FAQs before submitting your grant application!